In8Bio (INAB) Other Non-Current Assets (2020 - 2026)
In8Bio (INAB) posted Other Non-Current Assets of $220000.0 for Q1 2026, little changed sequentially from $220000.0 in Q4 2025, and down 18.22% YoY from $269000.0 in Q1 2025.
In8Bio (INAB) Other Non-Current Assets (2020 - 2026) Analysis & Trends
In8Bio has reported Other Non-Current Assets for 7 years, with the latest figure at $220000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 18.22% year-over-year to $220000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $220000.0 (down 18.22% YoY) and the FY2025 annual result came in at $220000.0, down 20.0% from the prior year.
- Other Non-Current Assets was little changed at $220000.0 in Q1 2026 per INAB's latest filing, from $220000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $275000.0 in Q4 2024 and troughed at $169000.0 in Q3 2025.
- A 5-year average of $248470.6 and a median of $254000.0 in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets surged 78.72% in 2022, then tumbled 34.75% in 2025.
- Over 5 years, Other Non-Current Assets stood at $255000.0 in 2022, then gained by 0.39% to $256000.0 in 2023, then climbed by 7.42% to $275000.0 in 2024, then slipped by 20.0% to $220000.0 in 2025, then changed by 0.0% to $220000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $220000.0, $220000.0, and $169000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | 176,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 176,000.00 |
| Mar 31, 2026 | 220,000.00 |
| Dec 31, 2025 | 220,000.00 |
| Sep 30, 2025 | 169,000.00 |
| Jun 30, 2025 | 271,000.00 |
| Mar 31, 2025 | 269,000.00 |
| Dec 31, 2024 | 275,000.00 |
| Sep 30, 2024 | 259,000.00 |
| Jun 30, 2024 | 259,000.00 |
| Mar 31, 2024 | 256,000.00 |
| Dec 31, 2023 | 256,000.00 |
| Sep 30, 2023 | 254,000.00 |
| Jun 30, 2023 | 253,000.00 |
| Mar 31, 2023 | 253,000.00 |
| Dec 31, 2022 | 255,000.00 |
| Sep 30, 2022 | 252,000.00 |
| Jun 30, 2022 | 252,000.00 |
| Mar 31, 2022 | 251,000.00 |
| Dec 31, 2021 | 251,000.00 |
| Sep 30, 2021 | 251,000.00 |